NEW YORK AND VANCOUVER, British Columbia, Oct. 21, 2024 (GLOBE NEWSWIRE) -- Bright Minds Biosciences Inc. (Bright Minds or the Company) (NASDAQ: DRUG), a biotechnology company focused on developing ...
TipRanks on MSN
Alto Neuroscience’s ALTO-101 Study: A Potential Game-Changer for Schizophrenia Treatment?
Alto Neuroscience, Inc. (($ANRO)) announced an update on their ongoing clinical study. Study Overview: Alto Neuroscience, Inc. is conducting a ...
– Enrollment remains ongoing in a Phase 2 proof-of-concept study of ALTO-101 in patients with CIAS – MOUNTAIN VIEW, Calif., October 03, 2025--(BUSINESS WIRE)--Alto Neuroscience, Inc. ("Alto") (NYSE: ...
"After successful use of the BNA platform to analyze the data from our Phase 1 study, we look forward to once again collaborating with the Firefly team at the conclusion of our Phase 2 program for our ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback